EP Patent

EP2845625A1 — Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome

Assigned to Gruenenthal GmbH · Expires 2015-03-11 · 11y expired

What this patent protects

The invention relates to tapentadol for use in the treatment of fibromyalgia or chronic fatigue syndrome.

USPTO Abstract

The invention relates to tapentadol for use in the treatment of fibromyalgia or chronic fatigue syndrome.

Drugs covered by this patent

tapentadol-hydrochloride (TAPENTADOL HYDROCHLORIDE)

Patent Metadata

Patent number: EP2845625A1
Jurisdiction: EP
Classification: —
Expires: 2015-03-11
Drug substance claim: No
Drug product claim: No
Assignee: Gruenenthal GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.